Olmetec Blood Pressure Drug Side Effects Class Action Lawsuit

Olmetec Blood Pressure Drug Side Effects Class Action Lawsuit

!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https';if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+'://platform.twitter.com/widgets.js';fjs.parentNode.insertBefore(js,fjs);}}(document, 'script', 'twitter-wjs');

lang: en_US

Share

Active

Join This Class Action

.documentsbtn span.plus,

.documentsbtn span.minus{

display:none;

}

.documentsbtn[aria-expanded="false"] span.plus,

.documentsbtn[aria-expanded="true"] span.minus{

display:block;

float: left;

margin: 0 10px 0px 0;

}

+ - Documents (4)

QC Jul 23, 2019 [en]

Amended Application for Authorization

QC Dec 06, 2018 [fr]

Preliminary Judgment 2

QC Dec 06, 2018 [fr]

Preliminary Judgment 1

QC Nov 04, 2016 [en]

Motion for Authorization

CONSUMER LAW GROUP has launched a Canadian-wide class action against Merck Canada Inc., Schering-Plough Canada Inc. and Daiichi Sankyo Company, Ltd., the manufacturers of OLMETEC and OLMETEC PLUS, on behalf of individuals who have suffered serious gastrointestinal side effects such as chronic diarrhea, Olmesartan-induced enteropathy (OAE), villous atrophy/blunting/damage, nausea, malnutrition, and dehydration after taking the blood pressure medication.

OLMETEC’s active ingredient is Olmesartan Medoxomil. OLMETEC PLUS’s active ingredients are Olmesartan Medoxomil and Hydrochlorothiazide. They are considered angiotensin II receptor blockers (ARB) and are sold as a treatment for hypertension (high blood pressure) and other medical conditions, including renal disease.

The U.S. equivalent, known as Benicar and Benicar HCT, are manufactured by Daiichi Sankyo. The maker